Following the September 6, 2024 public meeting hosted by the Reagan-Udall Foundation for the FDA in which agency officials joined representatives from the Department of Defense (DoD) and VA, patients, advocates, and industry representatives to discuss the current treatment landscape and what can be done to accelerate development of PTSD treatment, Reason for Hope and VMHLC have provided comments on advancing treatment for PTSD. "Recent trials with novel therapies like MDMA, p

Reason for Hope and VMHLC joined twelve other veteran service organizations and veterans groups in a letter to the Biden Administration to express their unwavering support for FDA approval for MDMA assisted therapy (MDMA-AT) for the treatment of Post-Traumatic Stress Disorder.

Reason for Hope, The Veteran Mental Health Leadership Coalition, BrainFutures, and the additional cosigners noted below provided comments on the draft guidance, Psychedelic Drugs: Considerations for Clinical Investigations / Guidance For Industry (“draft Guidance”), which the Food and Drug Administration (“FDA”) announced in the Federal Register on June 26, 2023. Read the Comments